USPTO Director Squires Issues Precedential Discretionary Denial in Magnolia Medical IPR – Targeting Litigation Leverage

USPTO Director John Squires issued a Director Discretionary Decision on May 14, 2026, denying institution of an inter partes review (IPR) petition and designating the opinion precedential. The decision, issued in a case where Magnolia Medical Technologies is the patent owner, makes explicit that “the lack of a jury verdict as to anticipation or obviousness in the now-completed jury trial does not entitle Petitioner to re-litigate the same issues at the Office.” The opinion is among the most assertive moves yet in Squires’ broader recalibration of IPR practice.

The decision converts the substantive reasoning behind a March 23 Notice of Denial into a framework intended to guide AIA proceedings generally. Director Squires reiterated that the America Invents Act envisioned inter partes review as an alternative to litigation, not a tool to harass patent owners or layer in tactical pressure on parallel court cases. Drawing on fifteen years of PTAB statistics, the opinion sets out six principles that should inform the institution analysis.

First, AIA proceedings are an alternative to litigation, not a harassment device. Second, serial petitions, follow-on petitions after losses in other forums, and inconsistent positions across forums all signal misuse of the system. Third, the petitioner’s profile matters: the scope of U.S.-based operations and small-business status carry weight. Fourth, AIA review is a public-interest mechanism rather than a vehicle for resolving private disputes, which remain the province of district courts. Fifth, courts’ scope of review of patent validity is broader than the Office’s. Sixth, both petitions and patent-owner responses should expressly address the public-interest factor when invoking Director Discretion.

Squires drew particular attention to filing concentration. According to the opinion, one study cited shows that “the top ten petitioners—most, if not all, of whom are market dominant companies—filed roughly 1,900 petitions, while the next 70 petitioners combined filed roughly the same number.” That kind of distribution, the Director argued, sits uncomfortably with the statutory aim of opening validity contests to parties who lack the resources to litigate in court.

In the specific case, the petitioner had turned to IPR after a completed jury trial closed without a verdict on anticipation or obviousness. Squires concluded that an unsuccessful run at the district court does not warrant a fresh attempt at the agency: the petitioner is not entitled to relitigate the same prior-art challenges at the Office simply because the jury was not asked to resolve them.

The opinion lists illustrative prior decisions to flesh out the analytical framework. Padagis US LLC v. Neurelis, Inc. (IPR2025-00464, designated informative on July 16, 2025) addressed examiner error. Revvo Techs., Inc. v. Cerebrum Sensor Techs., Inc. (IPR2025-00632, designated precedential on November 3, 2025) previewed similar reasoning on discretionary denial. Together with the new Magnolia Medical decision, they begin to populate a body of precedential and informative authority on how the Office should weigh litigation overlap, petitioner profile, and public interest.

Squires took office in September 2025 and has steadily centralized institution policy in the Director’s office. The thrust of his approach builds on the discretionary-denial reset that Acting Director Coke Morgan Stewart began in March 2025, but goes further by publishing more detailed precedential opinions under the current Director’s name and by elevating the public-interest factor as a recurring touchstone.

The practical consequences for IPR practice are significant. Portfolio-defense strategies that involve running multiple IPRs in parallel with district-court litigation now face an explicit, articulated risk of discretionary denial at the institution stage. Recent USPTO statistics already show IPR filings at the lowest level since AIA implementation, with ex parte reexamination overtaking IPR in volume for the first time. The new precedent is likely to amplify that shift. Patent owners can expect more leverage in arguing for denial when they can pair the public-interest factor with evidence about the petitioner’s litigation posture and market position.

The flip side is a narrower path for legitimate validity challenges, and a renewed debate over whether the Office is closing off a forum that Congress designed precisely to provide a faster, cheaper alternative to litigation. Practitioners are watching how the Office calibrates the discretionary framework so that it deters strategic IPRs by dominant players without choking off use of the system by small and mid-sized defendants. The next round of precedential and informative designations will indicate where the line is settling.

Sources:
– USPTO Director John A. Squires, Director Discretionary Decision (May 14, 2026, precedential)
– IPWatchdog, “Squires’ Latest Precedential Decision Slams Use of IPR for ‘Litigation Leverage,'” May 18, 2026
– Padagis US LLC v. Neurelis, Inc., IPR2025-00464, Paper 12 (Director July 16, 2025, informative)
– Revvo Techs., Inc. v. Cerebrum Sensor Techs., Inc., IPR2025-00632, Paper 20 (Director Nov. 3, 2025, precedential)